6月12日周四盘中，燃石医学(BNR.US)股价出现显著上涨，涨幅高达24.58%，引发市场广泛关注。这家专注于肿瘤患者基因检测的公司股价强劲上涨，主要得益于其创新产品在中国市场取得的重大突破。
据悉，燃石医学与迪哲医药(688192.SH)合作开发的EGFR exon20ins伴随诊断试剂盒于2024年10月获得监管部门批准。这项产品是中国首个基于NGS技术的肺癌伴随诊断产品，标志着公司在精准医疗领域取得重大进展。这一突破性成果不仅彰显了燃石医学在肿瘤诊断领域的技术优势，也为公司在竞争激烈的医疗器械市场中赢得了先机。
燃石医学专注于为肿瘤患者提供全面的基因检测服务，涵盖靶向治疗和免疫治疗等多个临床应用场景。公司的多基因平行检测服务能够为临床医生提供更精准的用药决策支持，有望显著提高癌症治疗的效果。随着精准医疗概念日益普及，市场对燃石医学这类专业的基因检测公司的未来发展前景持乐观态度，这也是推动其股价大幅上涨的重要因素之一。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.